All-trans retinoic acid (ATRA) is a metabolite of vitamin A and plays an important role in cell differentiation, proliferation, reproduction, and development. Recently, ATRA has been used in differentiation therapy for acute promyelocytic leukemia (APL). APL is a subtype of myeloid leukemia with a translocation between chromosomes 15 and 17, resulting in a fusion protein between PML and retinoic acid receptor (RAR)a. 1 ATRA therapy induces a high rate of complete remission without severe side effects. However, most patients who relapse after ATRA therapy have acquired ATRA resistance. This resistance seems to result from an insufficiently high plasma ATRA concentration during therapy. This phenomenon may be caused by the increased oxidative catabolism of ATRA by cytochrome P-450, increases in levels of cellular retinoic acid binding protein (CRABP), or multidrug-resistance (MDR) gene product. It may also be the result of some other cellular mechanism, as mutations in the RARa region of the PML/RARa fusion gene have been found in APL patients who relapse.
RAR belongs to a gene superfamily of hormone nuclear receptors that act as ligand-dependent transcriptional factors. 1 ATRA is a ligand of RAR and exerts its biologic effect by binding to RAR. RAR forms a heterodimeric complex with retinoid X receptors in the transactivation of target genes. The ligandreceptor complex binds in turn to the retinoic acid response elements (RARE) in their gene promoters.
The molecular mechanism responsible for the beneficial effect of ATRA therapy for APL and the mechanism of ATRAinduced differentiation in APL cells are under investigation. Several target genes of RAR have now been identified using the cDNA microarray system. 2 Therefore, it is reasonable to expect that the network of target genes affected by ATRAinduced differentiation will be elucidated in the relatively near future. Here we report the expression of CD38 and CCAAT/enhancer binding protein e (C/EBPe), which are target genes of RARa, in the blood cells of a patient with APL during ATRA therapy.
A 6-year-old girl developed a persistent fever and gingival bleeding. She was brought to her family physician, and routine evaluation disclosed anemia and thrombocytopenia. The patient was transferred immediately to Osaka Medical College Hospital for further evaluation and treatment.
Hematologic examination and bone marrow aspiration were performed, and the patient was diagnosed with APL. The bone marrow contained 92% promyelocytes with typical Auer bodies and Faggot cells. Cytogenic analysis revealed a t(15;17) translocation in 90% of the bone marrow cells. A reverse transcription-polymerase chain reaction (RT-PCR) was performed, and a PML/RAR a fusion RNA product was detected.
Oral ATRA treatment (23 mg/m 2 /day) was started in two divided doses, and was initially combined with blood transfusions. Within 2 weeks, all laboratory evidence of disseminated intravascular coagulation disappeared. The white blood cell (WBC) count rose to 47.0 Â 10 6 /ml without any evidence of retinoic acid syndrome, which is similar to respiratory distress syndrome and is characterized by fever, dyspnea, and fluid overload. Retinoic acid syndrome often is heralded by a rapid increase in the WBC count. Four weeks after ATRA administration, repeated bone marrow aspiration showed complete remission of the APL, but PCR for PML/RAR a was positive. The patient underwent three cycles of conventional consolidation chemotherapy (behenoyl cytarabine, predonisolone, 6-mercaptopurine, and daunorubicin). After 12 weeks, no PML/ RAR a was detected by PCR.
In this case, the dose of ATRA administered was only 50% of the standard therapeutic dose (ATRA; 45 mg/m 2 /day). This lower amount was used to prevent hyperleukocytosis and retinoic acid syndrome. Despite the reduced dose, hyperleukocytosis still occurred during ATRA administration. However, this patient did not develop retinoic acid syndrome and had no other evidence of toxicity besides dermatitis and dry lips.
The pharmacokinetics of ATRA were determined on the first day of therapy. 3 The area under the curve (AUC) was 424 h ng/l, C max was 234 ng/ml, the T max was 60 min, and the half-life was 42 min. These parameters were within the range of the remission group who received ATRA therapy. 3 During ATRA therapy, we also investigated the expression of C/EBPe and CD38, which are the target genes of RAR. C/EBP belongs to the basic leucine zipper class of transcriptional factors. The members of the C/EBP family play important roles in the proliferation and differentiation of a variety of mammalian cells, including adipocytes, hepatocytes, and myelocytes. C/EBPe has been identified as a potential regulator of myeloid differentiation and is critical for proper granulocytic development and function. 4 ATRA upregulates the expression of C/EBPe in parallel with the induction of granulocyte differentiation. Park et al 5 have reported that the C/EBPe promoter contains RARE, and C/EBPe expression is regulated transcriptionally by RAR.
We examined the expression of leukocyte C/EBPe before and after ATRA therapy by Western blot analysis. C/EBPe expression in leukocytes was higher on the 15th day of ATRA administration than it was at pretreatment (Figure 1) . The bone marrow sample obtained before treatment contained more than 80% promyelocytes by morphology. On day 15, hyperleukocytosis was observed. This finding shows that APL cells differentiate into granulocytes following ATRA administration and that the expression of C/EBPe in leukemic cells can be induced by retinoic acid through RAR. This case illustrates that ATRA can induce C/EBPe expression in leukemic cells in a patient with APL.
CD38 is expressed by lymphocyte precursors, activated lymphocytes, and mature plasma cells, and is well accepted as a marker of activation and differentiation. 6 The function of CD38 is to catalyze the synthesis of cyclic ADP-ribose from nicotinamide adenine dinucleotide (NAD), and cyclic ADPribose acts as a mediator, or modulator, of intracellular calcium mobilization. 7 In addition to affecting this enzymatic activity, CD38 may also play a role in cell growth, apoptosis, differentiation, and inflammation.
The expression of CD38 is induced by retinoic acid, vitamin D, and cytokines such as interferon-and interferon-a. Retinoic acid is a potent inducer of CD38 expression in the myeloid lineage. Kishimoto et al 7 reported that the CD38 gene contains RARE, which is located in the first intron. Therefore, retinoic acid-induced expression of the human CD38 gene is mediated transcriptionally through RARE. Moreover, it has been shown that retinoic acid has a marked effect on T-cell differentiation.
We monitored CD38 expression in normal T cells from pretreatment through remission on day 30 using flow cytometry (Figure 2 ). CD38 expression by CD4+ and CD8+ cells was greater after remission than it was at pretreatment. Interferonand interferon-a rapidly induce CD38 expression in mature tonsillar B cells and myeloid cells. 6 The plasma levels of these two cytokines did not change during ATRA therapy. Therefore, increased CD38 expression must have been caused by the effect of retinoic acid.
Drach et al
8 examined a wide range of ATRA concentrations in their study of CD38 expression in HL-60 cells. CD38 expression in ATRA-treated cells increased dose dependently. Treating HL-60 cells with 1 Â 10 À7 M ATRA, which is the generally accepted therapeutic concentration for patients with APL, increased CD38 expression. CD38 expression by peripheral blood promyelocytes in patients with APL also increases with ATRA administration.
In this case, the plasma ATRA concentrations were therapeutic for the treatment of APL, according to pharmacokinetic data. The upregulation of CD38 expression suggests that plasma ATRA levels in this patient should have been sufficient to induce differentiation in leukemic cells. However, it has not been established whether the therapeutic effect of ATRA levels in which CD38 expression in T cells is increased is similar to the therapeutic effect of ATRA levels that produce leukemia cell differentiation. This issue warrants further examination, and we should consider whether other, as of yet unknown, molecules contribute to the regulation of CD38 expression. However, it may be surmised that retinoic acid regulates CD38 expression in T cells because remission is induced easily and the plasma concentrations of the cytokines that induce CD38 expression do not change during ATRA administration. These findings suggest that monitoring CD38 expression in normal T cells may be a useful marker for determining the efficacy of ATRA levels during ATRA therapy based on the differentiation of APL cells. C/EBPe expression during ATRA therapy was detected by Western blot analysis using peripheral mononuclear cells (PBMC) and rabbit polyclonal anti-human C/EBPe. PBMC were isolated using mono-poly resolving medium. TO THE EDITOR Trioxide (As 2 O 3 ) represents a great advance in the management of patients with relapsed or refractory acute promyelocytic leukemia (APL). However, As 2 O 3 resistance has been reported at diagnosis or as arising during treatment with As 2 O 3 in some cases. Several investigators have studied the mechanisms of As 2 O 3 -resistance, and reported an alteration of cellular glutathione levels and the involvement of drug efflux pumps such as MDR-associated protein (MRP) and P-glycoprotein (P-gp). 1, 2 In some reports, drug-resistance modifiers restored the intracellular accumulation of As 2 O 3 .
2-4 Therefore, As 2 O 3 might also be affected by these transportation systems, and intracellular accumulation of As 2 O 3 may be decreased in As 2 O 3 -resistant APL cells. In this study, we aimed to clarify the relation between these drug-resistance mechanisms and As 2 O 3 -resistance in APL cells. We also assessed the intracellular accumulation of As 2 O 3 in APL cell lines and blast cells from patients with APL cells, because this has not been analyzed previously from the viewpoint of As 2 O 3 -resistance in APL.
Cells used in this study were an APL cell line (NB4) in which P-gp was undetectable, NB4 transfected with MDR-1 cDNA (NB4/MDR), As 2 O 3 -resistant NB4 (NB4/As) and blast cells from 14 patients with clinically ATRA-resistant APL including three patients with clinically As 2 O 3 -resistant APL. NB4/MDR and NB4/As cells were obtained as described in our previous reports. 8 The degree of dissociation between the fluorescence intensity (FI) of cells that reacted with MRK16 or MRPm6 MoAb and the FI of cells stained with respective control MoAb was analyzed by the channel-bychannel subtraction method, and the degree of dissociation was defined as the amount (%) of P-gp or MRP1.
6 P-gp function was determined by rhodamine-123 (Rh123) accumulation and its inhibition by PSC833 (Novartis Pharma, Basel, Switzerland) or MS209 (Mitsui Pragmatics, Tokyo, Japan).
6 MRP1 function was determined by calcein acetoxymethyl ester (calcein-AM) (Dojin Chem., Kumamoto, Japan) efflux and its inhibition by probenecid. 6 The accumulation (%) of Rh123 and the efflux (%) of calcein-AM were determined as reported previously. 6 The amount of mdr-1 and mrp-1 mRNA were determined by realtime PCR analysis. The primer set to amplify mdr-1 and mrp-1
